Yanan Li

TL;DR: During the epidemic period of COVID-19, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.

TL;DR: The findings suggest that older patients with risk factors are more likely to develop CVD and the development of CVD is an important negative prognostic factor which requires further study to identify optimal management strategy to combat the COVID-19 outbreak.

TL;DR: In this paper, the neurological manifestations of patients with coronavirus disease 2019 (COVID-19) were studied in three categories: central nervous system (CNS) symptoms or diseases (headache, dizziness, impaired consciousness, ataxia, acute cerebrovascular disease, and epilepsy), peripheral nervous system symptoms (hypogeusia, hyposmia, hypopsia, and neuralgia), and skeletal muscular symptoms.

TL;DR: Anti-TNFα (infliximab, a potent clinically used drug) treatment significantly ameliorate endothelial necroptosis, BBB destruction and improve stroke outcomes and suggest infliximab might serve as a potential drug for stroke therapy.